Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85 years of age in Greece: the GREVAXIMO study

BACKGROUND: Elderly people aged over 85 years were among the first groups to receive the BNT162b2 mRNA Covid-19 vaccine in Greece according to the national priority assignment policy. AIM: The aim of this study was to provide useful insight into the antibody generation taking place post-immunization...

Descripción completa

Detalles Bibliográficos
Autores principales: Kontopoulou, Konstantina, Nakas, Christos Theodore, Ainatzoglou, Alexandra, Ifantidou, Athina, Ntotsi, Paschalina, Katsioulis, Christos, Papazisis, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502633/
https://www.ncbi.nlm.nih.gov/pubmed/34633648
http://dx.doi.org/10.1007/s40520-021-01997-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502633/
https://www.ncbi.nlm.nih.gov/pubmed/34633648
http://dx.doi.org/10.1007/s40520-021-01997-7

Ejemplares similares